Objective. Our work aimed to assess, in real conditions, the association between cetuximab's cutaneous adverse drug reactions and the overall survival at 6 months for metastatic @entity14 (mCRC) and @entity135 . Method. We conducted a retrospective observational study. The 6-month survival was defined as the @entity1 's status evaluated six months after the first administration of cetuximab. Multivariate survival analysis was performed by the Cox model. Results. Between January 2004 to June 2010, 167 @entity1 have been included (97 @entity1 with a mCRC and 70 @entity1 with @entity135 ). The occurrence of at least one cutaneous adverse effect is associated with a significantly reduced risk of mortality at 6 months (total population, RR=0.34 [0.20-0.58], p<0.001; mCRC population, RR=0.45 [0.21-0.99], p=0.047; @entity135 population, RR=0.25 [0.13-0.50], p<0.001). Conclusion. These results show, for the first time in real conditions, the possible link between cutaneous adverse drugs reactions and 6-month survival.

[Cetuximab Cutaneous Adverse Drug Reactions: a Marker of Efficacy for Metastatic @entity14 and XXXX ?]

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head-neck cancer', 'a head-neck cancer'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']
@entity135 :: (MESH:D006258,Disease) :: ['Head-Neck Cancer']
